产前硫酸镁与新生儿不良结局:系统综述与荟萃分析
该系统综述与荟萃分析评估产前硫酸镁是否与意外新生儿不良结局相关,检索截至2019年9月,纳入197项研究(40项随机试验、138项非随机研究、19例病例报告)。随机试验显示硫酸镁与安慰剂/无治疗相比围产期死亡无 clear 差异(RR 1.01;95%CI 0.92-1.10;8项试验,13654名婴儿),未观察到 clear 的次要不良结局;非随机研究证据有限且偏倚风险中高。结论不支持产前硫酸镁有益指征与新生儿不良结局存在明确关联。
要点
- 随机试验中硫酸镁与安慰剂/无治疗相比围产期死亡无 clear 差异(RR 1.01;95%CI 0.92-1.10)。
- 随机试验未观察到 clear 的次要新生儿不良结局。
- 非随机研究中可能的危害证据有限,偏倚风险中高,样本小。
核心结论
- 研究结果不支持产前硫酸镁用于有益指征与新生儿不良结局之间存在明确关联。
研究设计与样本
- 系统综述与荟萃分析,检索CINAHL、Cochrane Library、LILACS、MEDLINE、Embase、TOXLINE和Web of Science(自建库至2019年9月3日)。
- 纳入随机、准随机和非随机试验、队列和病例对照研究及病例报告,评估产前硫酸镁用于子痫前期、子痫、胎儿神经保护或宫缩抑制,与安慰剂/无治疗或不同硫酸镁方案比较。
- 共纳入197项研究:40项随机试验(随机化19265名妇女及其婴儿)、138项非随机研究、19例病例报告;随机试验于1987年至2018年开展,16项在高收入国家、23项在低/中等收入国家、1项混合。
主要发现
- 随机试验中,硫酸镁与安慰剂/无治疗相比围产期死亡无 clear 差异(RR 1.01;95%CI 0.92至1.10;8项试验,13654名婴儿),不同方案间亦无 clear 差异。
- 随机试验未观察到 clear 的次要新生儿不良结局;非随机研究中识别出极少数值得进一步考虑的潜在不良结局。
临床怎么用
- 基于随机试验证据,产前硫酸镁用于子痫前期、子痫或胎儿神经保护时未显示与新生儿不良结局的明确关联。
- 非随机研究提示的潜在危害证据有限且偏倚风险中高,解读时应谨慎。
局限性
- 大多数研究缺失重要结局数据。
- 纳入研究存在异质性。
- 仅纳入已发表数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is widespread, increasing use of magnesium sulphate in obstetric practice for pre-eclampsia, eclampsia, and preterm fetal neuroprotection; benefit for preventing preterm labour and birth (tocolysis) is unproven. We conducted a systematic review and meta-analysis to assess whether antenatal magnesium sulphate is associated with unintended adverse neonatal outcomes. METHODS AND FINDINGS: CINAHL, Cochrane Library, LILACS, MEDLINE, Embase, TOXLINE, and Web of Science, were searched (inceptions to 3 September 2019). Randomised, quasi-randomised, and non-randomised trials, cohort and case-control studies, and case reports assessing antenatal magnesium sulphate for pre-eclampsia, eclampsia, fetal neuroprotection, or tocolysis, compared with placebo/no treatment or a different magnesium sulphate regimen, were included. The primary outcome was perinatal death. Secondary outcomes included pre-specified and non-pre-specified adverse neonatal outcomes. Two reviewers screened 5,890 articles, extracted data, and assessed risk of bias following Cochrane Handbook and RTI Item Bank guidance. For randomised trials, pooled risk ratios (RRs) or mean differences, with 95% confidence intervals (CIs), were calculated using fixed- or random-effects meta-analysis. Non-randomised data were tabulated and narratively summarised. We included 197 studies (40 randomised trials, 138 non-randomised studies, and 19 case reports), of mixed quality. The 40 trials (randomising 19,265 women and their babies) were conducted from 1987 to 2018 across high- (16 trials) and low/middle-income countries (23 trials) (1 mixed). Indications included pre-eclampsia/eclampsia (24 trials), fetal neuroprotection (7 trials), and tocolysis (9 trials); 18 trials compared magnesium sulphate with placebo/no treatment, and 22 compared different regimens. For perinatal death, no clear difference in randomised trials was observed between magnesium sulphate and placebo/no treatment (RR 1.01; 95% CI 0.92 to 1.10; 8 trials, 13,654 babies), nor between regimens. Eleven of 138 non-randomised studies reported on perinatal death. Only 1 cohort (127 babies; moderate to high risk of bias) observed an increased risk of perinatal death with >48 versus ≤48 grams magnesium sulphate exposure for tocolysis. No clear secondary adverse neonatal outcomes were observed in randomised trials, and a very limited number of possible adverse outcomes warranting further consideration were identified in non-randomised studies. Where non-randomised studies observed possible harms, often no or few confounders were controlled for (moderate to high risk of bias), samples were small (200 babies or fewer), and/or results were from subgroup analyses. Limitations include missing data for important outcomes across most studies, heterogeneity of included studies, and inclusion of published data only. CONCLUSIONS: Our findings do not support clear associations between antenatal magnesium sulphate for beneficial indications and adverse neonatal outcomes. Further large, high-quality studies (prospective cohorts or individual participant data meta-analyses) assessing specific outcomes, or the impact of regimen, pregnancy, or birth characteristics on these outcomes, would further inform safety recommendations. PROSPERO: CRD42013004451.
引用
- Shepherd E, Salam RA, Manhas D, et al. Antenatal magnesium sulphate and adverse neonatal outcomes: A systematic review and meta-analysis. PLoS Med. 2019. PMID: 31809499. doi:10.1371/journal.pmed.1002988
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。